Literature DB >> 25762166

Comparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population.

Yasunobu Hashimoto1, Toshio Takagi2, Tsunenori Kondo1, Junpei Iizuka1, Hirohito Kobayashi1, Kenji Omae1, Kazuhiko Yoshida1, Kazunari Tanabe1.   

Abstract

OBJECTIVE: We compared the clinical features and prognosis of renal cell carcinoma (RCC) between patients on hemodialysis (RCC-HD) and those in the general population (RCC-general).
METHODS: We included a total of 1,794 patients who underwent surgery (RCC-HD, 408; RCC-general, 1,386) and analyzed the clinical characteristics and oncological outcomes using a stage-for-stage analysis between the two groups.
RESULTS: In the RCC-HD group, the mean duration of dialysis before surgery was 120 months. Compared to the RCC-general group, the RCC-HD group tended to be younger (55 vs. 60 years, p < 0.0001) and more predominately male (84 % vs. 70 %, p < 0.0001), and the tumor size was smaller in this group (39 vs. 49 mm, p < 0.0001). The pathological characteristics of the RCC-HD group included a higher frequency of papillary tumors (22 % vs. 5 %, p < 0.0001) and stage I tumors (82 % vs. 68 %, p < 0.0001). During the follow-up period, 39 of patients (10 %) in the RCC-HD group and 193 patients (14 %) in the RCC-general group died of cancer. The patients on hemodialysis had better cancer-specific survival (CSS) than their counterparts (p = 0.0292) in the univariable analysis, but no significance was found in the multivariable analysis. In the stage-for-stage analysis, the 5-year CSS was similar between the two groups for each stage.
CONCLUSIONS: CSS appeared to be better in the RCC-HD group than in the RCC-general group, which may be associated with the higher incidence of stage I disease in the RCC-HD group. The comparable CSS between the groups in the stage-for-stage analysis supports this finding.

Entities:  

Keywords:  Hemodialysis; Kidney neoplasm; Nephrectomy; Prognosis

Mesh:

Year:  2015        PMID: 25762166     DOI: 10.1007/s10147-015-0812-9

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  16 in total

1.  Overview of regular dialysis treatment in Japan (as of 31 December 2009).

Authors:  Shigeru Nakai; Kunitoshi Iseki; Noritomo Itami; Satoshi Ogata; Junichiro James Kazama; Naoki Kimata; Takashi Shigematsu; Toshio Shinoda; Tetsuo Shoji; Kazuyuki Suzuki; Masatomo Taniguchi; Kenji Tsuchida; Hidetomo Nakamoto; Hiroshi Nishi; Seiji Hashimoto; Takeshi Hasegawa; Norio Hanafusa; Takayuki Hamano; Naohiko Fujii; Ikuto Masakane; Seiji Marubayashi; Osamu Morita; Kunihiro Yamagata; Kenji Wakai; Atsushi Wada; Yuzo Watanabe; Yoshiharu Tsubakihara
Journal:  Ther Apher Dial       Date:  2012-02       Impact factor: 1.762

2.  Renal cell carcinoma detected by screening shows better patient survival than that detected following symptoms in dialysis patients.

Authors:  Isao Ishikawa; Ryumon Honda; Yuichi Yamada; Tatsuyuki Kakuma
Journal:  Ther Apher Dial       Date:  2004-12       Impact factor: 1.762

3.  Renal cell carcinomas in haemodialysis patients: does haemodialysis duration influence pathological cell types and prognosis?

Authors:  Naoto Sassa; Ryohei Hattori; Toyonori Tsuzuki; Yoshihiko Watarai; Akitoshi Fukatsu; Satoshi Katsuno; Tosinori Nishikimi; Takashi Fujita; Kenji Ohmae; Momokazu Gotoh
Journal:  Nephrol Dial Transplant       Date:  2010-09-23       Impact factor: 5.992

4.  Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population.

Authors:  Yann Neuzillet; Xavier Tillou; Romain Mathieu; Jean-Alexandre Long; Marc Gigante; Philippe Paparel; Laura Poissonnier; Hervé Baumert; Bernard Escudier; Hervé Lang; Nathalie Rioux-Leclercq; Pierre Bigot; Jean-Christophe Bernhard; Laurence Albiges; Laurence Bastien; Jacques Petit; Fabien Saint; Franck Bruyere; Jean-Michel Boutin; Nicolas Brichart; Georges Karam; Julien Branchereau; Jean-Marie Ferriere; Hervé Wallerand; Sébastien Barbet; Hicham Elkentaoui; Jacques Hubert; Benoit Feuillu; Pierre-Etienne Theveniaud; Arnauld Villers; Laurent Zini; Aurélien Descazeaux; Morgan Roupret; Benoit Barrou; Karim Fehri; Thierry Lebret; Jacques Tostain; Jean-Etienne Terrier; Nicolas Terrier; Lucille Martin; Fabrice Dugardin; Ismaël Galliot; Frédéric Staerman; Marie-Dominique Azemar; Jacques Irani; Baptiste Tisserand; Marc-Olivier Timsit; Federico Sallusto; Pascal Rischmann; Laurent Guy; Antoine Valeri; Charles Deruelle; Abdel-Rahmène Azzouzi; Denis Chautard; Arnaud Mejean; Laurent Salomon; Jérôme Rigaud; Christian Pfister; Michel Soulié; François Kleinclauss; Lionel Badet; Jean-Jacques Patard
Journal:  Eur Urol       Date:  2011-03-02       Impact factor: 20.096

5.  Somatic mutations of the von Hippel-Lindau disease gene in renal carcinomas occurring in patients with long-term dialysis.

Authors:  Hitoshi Inoue; Norio Nonomura; Yasuyuki Kojima; Masahiro Shiba; Daizo Oka; Yasuyuki Arai; Masashi Nakayama; Hitoshi Takayama; Kazuo Nishimura; Hiroshi Mori; Akihiko Okuyama
Journal:  Nephrol Dial Transplant       Date:  2007-04-16       Impact factor: 5.992

6.  Renal cell carcinoma of end-stage renal disease: an analysis of chromosome 3, 7, and 17 abnormalities by microsatellite amplification.

Authors:  M D Hughson; S Bigler; K Dickman; G Kovacs
Journal:  Mod Pathol       Date:  1999-03       Impact factor: 7.842

Review 7.  2004 WHO classification of the renal tumors of the adults.

Authors:  Antonio Lopez-Beltran; Marina Scarpelli; Rodolfo Montironi; Ziya Kirkali
Journal:  Eur Urol       Date:  2006-01-17       Impact factor: 20.096

Review 8.  Renal cancer complicating acquired cystic kidney disease.

Authors:  J T Marple; M MacDougall; A M Chonko
Journal:  J Am Soc Nephrol       Date:  1994-06       Impact factor: 10.121

9.  Present status of renal cell carcinoma in dialysis patients in Japan: questionnaire study in 2002.

Authors:  Isao Ishikawa
Journal:  Nephron Clin Pract       Date:  2004

10.  Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand.

Authors:  John H Stewart; Gherardo Buccianti; Lawrence Agodoa; Ryszard Gellert; Margaret R E McCredie; Albert B Lowenfels; Alex P S Disney; Robert A Wolfe; Peter Boyle; Patrick Maisonneuve
Journal:  J Am Soc Nephrol       Date:  2003-01       Impact factor: 10.121

View more
  5 in total

1.  Outcome of advanced renal cell carcinoma arising in end-stage renal disease: comparison with sporadic renal cell carcinoma.

Authors:  Hiroki Ishihara; Hironori Fukuda; Hidekazu Tachibana; Kazuhiko Yoshida; Hirohito Kobayashi; Toshio Takagi; Junpei Iizuka; Hideki Ishida; Yoji Nagashima; Tsunenori Kondo; Kazunari Tanabe
Journal:  Clin Exp Nephrol       Date:  2021-02-27       Impact factor: 2.801

2.  Rapidly progressing programmed cell death 1 inhibitor-related pneumonitis in a hemodialytic patient with metastatic renal cell carcinoma.

Authors:  Yoshiaki Matsumura; Yusuke Iemura; Shinji Fukui; Yoshihiro Tatsumi; Yoriaki Kagebayashi; Shoji Samma
Journal:  IJU Case Rep       Date:  2019-04-10

3.  Outcomes of arteriovenous access among cancer patients requiring chronic haemodialysis.

Authors:  Seonjeong Jeong; Hyunwook Kwon; Jai Won Chang; Youngjin Han; Tae-Won Kwon; Yong-Pil Cho
Journal:  BMC Nephrol       Date:  2020-07-23       Impact factor: 2.388

4.  Computed tomography imaging characteristics of clear cell papillary renal cell carcinoma.

Authors:  Taro Banno; Toshio Takagi; Tsunenori Kondo; Kazuhiko Yoshida; Junpei Iizuka; Masayoshi Okumi; Hideki Ishida; Satoru Morita; Yoji Nagashima; Kazunari Tanabe
Journal:  Int Braz J Urol       Date:  2020 Jan-Feb       Impact factor: 1.541

5.  Clinical features and outcomes in kidney transplant recipients with renal cell carcinoma: a single-center study.

Authors:  Keun Hoi Park; Jung A Yoon; Hak Soo Kim; Hyosang Kim; Su-Kil Park; Young Hoon Kim; Bumsik Hong; Dalsan You; In Gab Jeong; Chung Hee Baek
Journal:  Kidney Res Clin Pract       Date:  2019-12-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.